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955Immortal Time Bias and
the Use of IVC FiltersWe commend the RIETE (Computerized Registry
of Patients with Venous Thromboembolism) group
for attempting to analyze the beneﬁts of use of an
inferior vena cava (IVC) ﬁlter after acute pulmonary
embolism (PE) using their large prospectively col-
lected registry (1). Their propensity-matched analysis
showed a lower risk-adjusted PE-related mortality
rate in patients who received an IVC ﬁlter compared
those who did not. However, we wish to point out
a signiﬁcant source of bias in this observational
study that cannot be adjusted for with the use of
propensity matching.
The bias we refer to is termed “immortal time bias”
(2). This bias is frequently encountered when
analyzing the effectiveness of an intervention, such
as use of an IVC ﬁlter, when using observational data.
The placement of a ﬁlter also depends on meeting
some clinical criteria, having a physician available to
place the ﬁlter, and the patient’s clinical condition.
In more critically ill patients, insertion of a ﬁlter
may not be possible and death may occur before
placement of the ﬁlter. In analyzing the data, if
simply comparing the outcomes of patients with an
IVC ﬁlter versus those without, the results are biased.
All patients who received a ﬁlter were alive at the
time of the procedure (hence, they were “immortal”
up to the time the ﬁlter was placed), whereas the
patients who did not receive a ﬁlter included those
who may have died before a ﬁlter could be placed.
This distinction between the 2 groups is important;
upwards of 30% of PE-related mortality occurs within
the ﬁrst 24 h of hospitalization (3). In the study by
Muriel et al. (1), in the patients who received an IVC
ﬁlter, the authors started the clock on the primary
outcome of 30-day mortality on the day the ﬁlter was
placed; however, in the patients who did not receive
a ﬁlter, it was considered to be when anticoagulation
was started. A better way of analyzing these data
would be to use the admission date or the date of
diagnosis of PE as the anchor time and model death
due to PE by using a Cox proportional hazard model,
entering use of an IVC ﬁlter as a time-dependent
covariate. The hazard associated with use of a ﬁlter is
compared with the hazard of not using a ﬁlter in
patients who are alive on the same day. Using this
methodology, all patients who were not treated with
a ﬁlter but who died early after diagnosis of PE
are excluded from calculation of the relative hazard
associated with use of a ﬁlter. Alternatively, patients
could be matched on both propensity score and beingalive on the day of placement of the ﬁlter, thereby
excluding those who died before the intervention
could be completed. We suggest that the authors use
one of these suggested methodologies to determine
if the hazard ratio for PE-related mortality is similar
or signiﬁcantly different between those with and
without a ﬁlter.
The authors raise several interesting points, but
we ultimately agree with the conclusion of Dr. Morris
in the accompanying editorial (4). The onlyway to truly
settle the controversial issue of whether ﬁlters are
beneﬁcial in patients who cannot be anticoagulated
is by conducting a well-designed clinical trial.
However, performing such a trial will be difﬁcult.
Informed consent will have to be obtained quickly,
followed by rapid randomization and expeditious
insertion of the IVC ﬁlter. Until that time, clinicians
must try to make inferences from observational
studies that have unmeasured confounders as well as
immortal time bias. We believe the results of such
analyses should not have any major impact on
venous thromboembolism guidelines or clinical
practice.*Timothy M. Fernandes, MD, MPH
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Use of IVC FiltersWe thank Drs. Fernandes and White for their
thoughtful comments about our registry-based retro-
spective cohort study of patients with acute venous
thromboembolism (1). We agree that the start time of
follow-up and treatment status in the design and
analysis of our study (1) might have introduced
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956immortal time bias (2) and subsequently affected
the results of the study. To address this concern, as
suggested in their letter to the editor, we reanalyzed
the data after matching for propensity score and
being alive on the day of ﬁlter placement. We
identiﬁed 8 patients (8 of 344 [2.3%]; 95% conﬁdence
interval [CI]: 0.7% to 3.9%) in the control group
who died before insertion of the ﬁlter, and we
removed the matched pairs from the reanalysis. The
propensity-based matching of patients yielded 336
patients with an inferior vena cava ﬁlter and 336
patients without a ﬁlter. We did not detect a
difference in mortality between patients who
received a ﬁlter and those who did not (6.8% vs.
8.9%; risk difference: 2.1% [95% CI: 6.3% to 2.0%];
p ¼ 0.32), although the clinically relevant trend
favored treatment with a ﬁlter. Analysis of propensity
score–matched pairs showed a statistically signiﬁcant
lower risk of pulmonary embolism–related mortality
for patients with a ﬁlter compared with those
without a ﬁlter (0.9% vs. 3.3%; risk difference: 2.4%
[95% CI: 4.9% to 0.2%]; p ¼ 0.04). Thus, after
addressing the concerns outlined in the letter to the
editor, we have results and conclusions similar to
those described in the study report (1).
A randomized trial is a powerful tool because it
enables clinical researchers to evaluate the efﬁcacy of
therapies without worrying about unmeasured con-
founders and some types of bias such as immortal
time bias. Although we agree that a randomized
controlled trial would provide the strongest evidence
regarding the efﬁcacy and safety of inferior vena cava
ﬁlters in patients with an acute venous thromboem-
bolism and a contraindication to anticoagulation, the
ethical issues associated with using a no-treatment
control group would likely prevent the performance
of such a trial. If it is not feasible to conduct a well-
designed randomized trial, investigators may use
observational studies to examine and infer treat-
ment effects. Although retrospective observational
studies may have various types of bias, propensity
scores may reduce the impact of any imbalance in
pre-treatment patient characteristics and may
address concerns about confounding. Studies have
found fairly good agreement between treatment ef-
fects in propensity score–based observational car-
diovascular studies compared with those in
randomized trials (3).
In conclusion, despite its inherent limitations,
our study shows provocative results regarding the
potential survival beneﬁt associated with use of
inferior vena cava ﬁlters in patients with acute
venous thromboembolism and absolute or relative
contraindications to anticoagulant therapy. Weencourage further assessment of the validity of
these ﬁndings.*David Jiménez, MD, PhD
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Effective Dose for
Cardiovascular CTWe read with interest the excellent report by Einstein
et al. (1) and the accompanying pragmatic editorial
(2). We support the laudable aim of involving
patients in the discussion of radiation exposure as
part of the clinical decision process, but we wish
to highlight a couple of areas for cardiovascular
computed tomography (CT) speciﬁcally that require
expert consensus to ensure this process is robust.
Dose calculation in cardiovascular CT is a complex
ﬁeld of medical physics, and the lack of clarity on
even the fundamentals clearly needs to be addressed.
First, the determination of an effective dose for pro-
cedures such as cardiovascular CT remains contro-
versial, while the lack of cardiovascular CT dose
reference levels and current benchmarking of insti-
tutional practice against these makes generalization
of dose potentially meaningless.
Several different conversion factors are currently
used in published reports when converting dose-
length product into an effective radiation dose (in
mSv) delivered to a patient. Aside from the fact that
these conversion factors were not designed to be
